ABUS vs REPL vs ASMB vs ALNY vs BMY

For growth investors, Assembly Biosciences, Inc.

(ASMB) is the stronger pick with 153. 5% revenue growth year-over-year, versus -0. 2% for Bristol-Myers Squibb Company (BMY). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Arbutus Biopharma Corporation (ABUS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

3x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8. 9x.

Over the past 5 years, Alnylam Pharmaceuticals, Inc.

(ALNY) delivered a total return of +125. 4%, compared to -90. 7% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: ALNY returned +411. 9% versus REPL's -78. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bristol-Myers Squibb Company (BMY) is the lower-risk stock at 0.

50β versus Assembly Biosciences, Inc. 's 1. 67β — meaning ASMB is approximately 232% more volatile than BMY relative to the S&P 500. On balance sheet safety, Arbutus Biopharma Corporation (ABUS) carries a lower debt/equity ratio of 1% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Assembly Biosciences, Inc.

(ASMB) is pulling ahead at 153. 5% versus -0. 2% for Bristol-Myers Squibb Company (BMY). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to 5. 2% for Replimune Group, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bristol-Myers Squibb Company (BMY) is the more profitable company, earning 14.

6% net margin versus -237. 9% for Arbutus Biopharma Corporation — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMY leads at 26. 3% versus -271. 0% for ABUS. At the gross margin level — before operating expenses — ASMB leads at 99. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8.

9x forward P/E versus 44. 2x for Alnylam Pharmaceuticals, Inc. — 35. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for REPL: 274. 3% to $12. 50.

In this comparison, BMY (4.

4% yield) pays a dividend. ABUS, REPL, ASMB, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bristol-Myers Squibb Company (BMY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

50), 4. 4% yield). Assembly Biosciences, Inc. (ASMB) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BMY: +6. 7%, ASMB: -47. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ABUS is a small-cap high-growth stock; REPL is a small-cap quality compounder stock; ASMB is a small-cap high-growth stock; ALNY is a mid-cap high-growth stock; BMY is a mid-cap deep-value stock. BMY pays a dividend while ABUS, REPL, ASMB, ALNY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.